{"title":"Rien de plus à offrir.","authors":"Jean-Luc Vonnez","doi":"10.53738/REVMED.2025.21.910.574","DOIUrl":"https://doi.org/10.53738/REVMED.2025.21.910.574","url":null,"abstract":"","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 910","pages":"574-575"},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143664452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laurie Cantini, Julia Lelièvre, Gaëlle Terrettaz, Rossalin Tzompov, Luca Zellweger
{"title":"Des aiguilles pour une grossesse plus confortable.","authors":"Laurie Cantini, Julia Lelièvre, Gaëlle Terrettaz, Rossalin Tzompov, Luca Zellweger","doi":"10.53738/REVMED.2025.21.909.507","DOIUrl":"https://doi.org/10.53738/REVMED.2025.21.909.507","url":null,"abstract":"","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 909","pages":"507-508"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Rheumatoid arthritis resistant to our treatments, what to do?]","authors":"Thomas Reygaerts","doi":"10.53738/REVMED.2025.21.909.494","DOIUrl":"https://doi.org/10.53738/REVMED.2025.21.909.494","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) can be classified as « resistant » or « difficult to treat » when there is no response to multiple lines of treatment and/or persistent symptoms that reduce the patients quality of life. Resistant RA represents a high-risk population for comorbidities. These patients often have more comorbidities, more extra-articular manifestations of their RA, have more disadvantaged social backgrounds, and frequently receive fewer conventional disease-modifying antirheumatic drugs. Managing resistant RA requires a reevaluation of the mechanisms causing persistent « inflammation » or « symptoms » as well as the comorbidities and interfering conditions of the patient. Often, these patients will require optimization of both immunological and non-immunological therapies-a true challenge for clinicians.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 909","pages":"494-499"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Injection hebdomadaire d’insuline : simplification de la prise en charge du diabète ?","authors":"Nicolas Fourré","doi":"10.53738/REVMED.2025.21.909.515","DOIUrl":"https://doi.org/10.53738/REVMED.2025.21.909.515","url":null,"abstract":"","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 909","pages":"515"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Treatments de-escalation in rheumatoid arthritis].","authors":"Marie Bishara, Thomas Hügle","doi":"10.53738/REVMED.2025.21.909.486","DOIUrl":"https://doi.org/10.53738/REVMED.2025.21.909.486","url":null,"abstract":"<p><p>The number of rheumatoid arthritis patients in clinical remission has increased dramatically. We owe this progress to the advent of biotherapy in the 1990s, but also to a more focused therapeutic approach. Managing remission is therefore a contemporary challenge and raises many questions: Do biotherapies lead to a cure or to drug-induced remission? What are the chances of reducing or stopping treatment? What factors are associated with successful discontinuation? How and in what order to proceed when patients are taking several treatments at the same time? In this article, concrete, pragmatic answers based on the latest recommendations and current knowledge are provided.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 909","pages":"486-491"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment rendre le dépistage du cancer du poumon accessible aux populations vulnérables du canton de Vaud ?","authors":"Kylian Gauteron, Lydia Hayenga, Sarah Hediger","doi":"10.53738/REVMED.2025.21.909.509","DOIUrl":"https://doi.org/10.53738/REVMED.2025.21.909.509","url":null,"abstract":"","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 909","pages":"509-511"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Emerging therapies for inflammatory rheumatic diseases].","authors":"Florence Fourel, Diana Dan, Alexandre Dumusc","doi":"10.53738/REVMED.2025.21.909.478","DOIUrl":"https://doi.org/10.53738/REVMED.2025.21.909.478","url":null,"abstract":"<p><p>Rheumatologists face daily challenges in managing inflammatory rheumatic diseases (rheumatoid arthritis, axial spondylarthritis, and psoriatic arthritis). Significant advancements in our therapeutic arsenal have occurred over the past decades. However, achieving remission remains an unattainable goal for many patients, highlighting the need for new treatment options. This article summarizes findings presented at recent European and American rheumatology congresses, focusing on current practice evaluations, new drugs and therapeutic classes, and innovative uses of existing medications, including residual level monitoring.</p>","PeriodicalId":21286,"journal":{"name":"Revue medicale suisse","volume":"21 909","pages":"478-482"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143617086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
